Meaningful Evidence
Nevro’s unique PDN indication is the outgrowth of years of investments in clinical trials culminating with the SENZA-PDN, the largest RCT evaluating SCS for PDN to date.
Relief, multiplied.
Introducing HFX for PDN
The SCS system approved by the FDA with a specific indication for Painful Diabetic Neuropathy.
Excellent Safety and Efficacy Profile
Within the SENZA-PDN, 10 kHz Therapy demonstrated exceptional outcomes across responder rates, pain relief, and even sensory response.
Direct Neural Inhibition With
10 kHz Therapy
Uniquely Possible With
10 kHz Therapy
Historically, PDN patients have struggled with a lack of treatment options when CMM fails. Now, 10 kHz Therapy and a unique mechanism of action offer new potential for relief.